<DOC>
	<DOCNO>NCT01935167</DOCNO>
	<brief_summary>Phase 2 clinical study evaluate efficacy safety DW1029M microalbuminuria Patients With Diabetic Nephropathy</brief_summary>
	<brief_title>To Determine Efficacy Safety DW1029M Microalbuminuria Patients With Diabetic Nephropathy</brief_title>
	<detailed_description>A Phase Ⅱ , prospective , 24 week , double-blind , placebo-controlled , randomize , multi-center clinical trial evaluation efficacy safety DW1029M microalbuminuria Patients With Diabetic Nephropathy</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Has confirm diabetic mellitus prior 6years Has confirm microalbuminuria 30 ~ 299㎍/㎎creatinine prior 5months one time microalbuminuria 30 ~ 299㎍/㎎creatinine screening period Blood Pressure ( BP ) ≤ 150 / 90 mmHg estimate glomerular filtration rate ( eGFR ) ≥ 30 ml/min/1.73m2 Hemoglobin A1c ( HbA1c ) ≤ 9 % Low density lipoprotein ( LDLC ) ≤ 130mg/dl kidney liver disease follow i.Serum Creatinine &gt; 2.0mg/dl ii.Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &gt; 2 x Upper Limit Normal ( ULN ) iii.Total Bilirubin &gt; 2 x ULN Organic gastrointestinal disorder Chronic gastroenterologic disorder prior 6 month follow [ NOTE ] Active Crohn 's disease , Active ulcerative colitis , Chronic peptic ulcer disease , etc . cardiovascular disease prior 3 month follow [ NOTE ] Unstable angina pectoris , Myocardial infarction , Coronary artery bypass surgery , Percutaneous Transluminal Coronary Angioplasty , transient ischemic attack , cerebrovascular accident etc .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Microalbuminuria</keyword>
</DOC>